BusinessEsperion to Participate in Fireside Chat at the 16th Annual Needham Healthcare ConferenceBy Nasdaq OMXMar 28, 2017, 8:30 PM UTC
BusinessEsperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication for Bempedoic AcidBy Nasdaq OMXMar 20, 2017, 11:30 AM UTC
BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:31 PM UTC
BusinessEsperion Announces Initiation of Phase 2 Triplet Oral Therapy Study of Bempedoic Acid/Ezetimibe/AtorvastatinBy Nasdaq OMXMar 7, 2017, 1:30 PM UTC
BusinessEsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific SessionBy Nasdaq OMXMar 6, 2017, 1:33 PM UTC
BusinessEsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific SessionBy Nasdaq OMXMar 6, 2017, 1:33 PM UTC
BusinessEsperion Announces Oral Presentation on Genetic Validation of ATP Citrate Lyase Inhibition at the American College of Cardiology 66th Annual Scientific SessionBy Nasdaq OMXMar 6, 2017, 1:33 PM UTC
BusinessEsperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in Patients with HypercholesterolemiaBy Nasdaq OMXJan 25, 2017, 1:05 PM UTC
